Trials / Completed
CompletedNCT00725933
Administration of BIIB028 to Subjects With Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of BIIB028 Administered to Subjects With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Safety and Tolerability of BIIB028
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BIIB028 | IV infusion administered twice weekly until disease progression or unacceptable toxicity |
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-01
- First posted
- 2008-07-31
- Last updated
- 2017-01-09
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00725933. Inclusion in this directory is not an endorsement.